Evidence-Based Combination Treatment for RA-ILD

First-Line Treatment Approach

• The American College of Rheumatology recommends mycophenolate as the preferred first-line immunosuppressive agent for RA-ILD, typically dosed at 1000-1500 mg twice daily with monitoring of complete blood count every 2-4 months 1, 3
• Azathioprine serves as a conditionally recommended alternative first-line option when mycophenolate is not tolerated or contraindicated 1, 2
• Cyclophosphamide represents another first-line alternative, particularly for more severe or rapidly progressive disease 1, 2
• Short-term glucocorticoids (≤3 months) are conditionally recommended as part of initial combination therapy for RA-ILD 1, 2

Treatment of Progressive RA-ILD Despite First-Line Therapy

• Mycophenolate, rituximab, or cyclophosphamide are conditionally recommended if not already used as first-line agents for progressive RA-ILD 1, 4
• Pirfenidone is conditionally recommended as an add-on therapy specifically for progressive RA-ILD 1, 2, 4
• Nintedanib is conditionally recommended as a treatment option for progressive RA-ILD 1, 4
• Tocilizumab is conditionally recommended for progressive RA-ILD despite first-line treatment 1, 2, 4

Management of Rapidly Progressive RA-ILD

• Upfront combination therapy (double or triple therapy) is conditionally recommended over monotherapy for rapidly progressive ILD 1, 2, 4
• Pulse intravenous methylprednisolone is conditionally recommended as first-line treatment for rapidly progressive RA-ILD 1, 2, 4
• Rituximab, cyclophosphamide, IVIG, mycophenolate, calcineurin inhibitors, or JAK inhibitors are all conditionally recommended first-line options that can be combined for rapidly progressive RA-ILD 1, 2, 4

Monitoring Strategy

• Pulmonary function tests (PFTs) including forced vital capacity (FVC) and diffusing capacity (DLCO) should be performed every 3-6 months to assess disease progression 3, 5
• High-resolution CT scanning at baseline and annually (or with significant PFT changes) is recommended to evaluate disease progression 3

Critical Pitfalls to Avoid

• Avoid overreliance on glucocorticoids for long-term management given the substantial adverse effect profile without proven long-term efficacy 1, 3

Multidisciplinary Approach

• Management decisions should involve collaboration between rheumatologists and pulmonologists to balance control of articular disease with ILD progression 5